Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-70

milward:  "The top notch data due to be released this December is already factored into todays share price."

milward:  On May 16th 2018 (when IMU's share-price was at around 3.7 cents) you did post the following:
"In the 2017 imugene immuno oncology expert briefing Axel Hoos said the mimotope platform makes immugene much more valuable than just HER-Vaxx alone due to the multiple potential cancer indications."

Now fast forward to November 2018 when IMU is trading at - what I would consider a measly - share-price level of around the 2 cents mark, you mention that you :  "don't expect any major change in the share price when this data is released" (in December 2018, that is).

I just wonder why you are seeing 'things' so conservatively from a valuation point of view??  OR: just perhaps I am far too 'bullish' in my perception that IMU currently is strongly under-valued??  
Many thanks in advance for comments by anyone that cares to comment.

Wishing all IMU holders the best.  May Imugene bring the necessary relief to cancer sufferers as early/quickly as possible !!

wasa